Wilbanks Smith & Thomas Asset Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,000	Closed	-$18K	–	1552
2018 Q3	$18K	Buy	+1,000	New	+$17.2K	﹤0.01%	919

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's ECYT Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 1,000 shares — an estimated $18K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in ECYT in Q3 2018 and held it in 1 quarter. The position peaked at $18K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Wilbanks Smith & Thomas Asset Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Wilbanks Smith & Thomas Asset Management sold 1,000 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $18K.
Wilbanks Smith & Thomas Asset Management first reported a position in Endocyte, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
Wilbanks Smith & Thomas Asset Management's Endocyte, Inc. Common Stock position peaked at $18K in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.